

7<sup>th</sup> February, 2022

To,  
Department of Corporate Services

**Bombay Stock Exchange Ltd.**

1st Floor, P.J. Towers,  
Dalal Street, Fort,  
Mumbai: 400001.  
Scrip Code: **BSE – 524500**

To,  
Corporate Listing Department

**National Stock Exchange of India Ltd.**

Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051.  
Scrip Code: **NSE – KILITCH**

Respected Sir/Madam,

**Sub: Intimation of Board Meeting for the unaudited Financial Results for the quarter ended 31st December, 2021**

We wish to inform you that the meeting of the Board of Directors of the Company will be held on Monday, **14<sup>th</sup> February, 2022** at the Corporate Office of the Company at Mumbai at 04.00 P.M.:

- To Consider and approve the Standalone and Consolidated Un-audited Financial Result of the Company for the quarter ended 31<sup>st</sup> December, 2021;
- Any other matter with the permission of the Chair.

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE, the Trading Window has been closed with effect from Saturday, 1<sup>st</sup> January 2022 and shall continue to remain closed till 48 hours after the announcement of the financial results on 14<sup>th</sup> February, 2022.

During the aforesaid period when the Trading Window is closed, designated persons including Promoters, Directors, connected persons, the insiders and their immediate relatives shall not trade in Company's shares / securities.

The above intimation is given to you pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.

Thanking You,  
Yours faithfully,

For Kilitch Drugs (India) Limited

  
**Mukund Mehta**  
(Managing Director)  
DIN:00147876

